First human trial launches for experimental cancer drug targeting HER2 tumors
NCT ID NCT05957536
Summary
This is the first human study of an experimental drug called D3L-001 for people with advanced cancers that test positive for a protein called HER2. The main goal is to find a safe dose and check for side effects in about 128 participants. Researchers will also gather early information on whether the drug helps control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER-2 POSITIVE ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
D3 Bio Investigative Site
RECRUITINGStanford, California, 94305, United States
-
D3 Bio Investigative Site
RECRUITINGBoston, Massachusetts, 02215, United States
-
D3 Bio Investigative Site
RECRUITINGNew York, New York, 10065, United States
-
D3 Bio Investigative Site
TERMINATEDSan Antonio, Texas, 78229, United States
-
D3 Bio Investigative Site
RECRUITINGSydney, New South Wales, 2109, Australia
-
D3 Bio Investigative Site
RECRUITINGMalvern, Victoria, 3144, Australia
-
D3 Bio Investigative Site
RECRUITINGHarbin, Heilongjiang, 150088, China
-
D3 Bio Investigative Site
RECRUITINGShanghai, Shanghai Municipality, 200025, China
-
D3 Bio Investigative Site
RECRUITINGHangzhou, Zhejiang, 310022, China
Conditions
Explore the condition pages connected to this study.